LTPA2017035I1 - Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu - Google Patents

Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Info

Publication number: LTPA2017035I1
Authority: LT; Lithuania
Prior art keywords: morphine; antibody; treatment; combination
Prior art date: 2009-08-14

Application number

LTPA2017035C

Other languages

English (en)

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-14

Filing date

2017-10-31

Publication date

2017-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-10-31 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2017-11-27 Publication of LTPA2017035I1 publication Critical patent/LTPA2017035I1/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTPA2017035C 2009-08-14 2017-10-31 Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu LTPA2017035I1 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09010489		2009-08-14
PCT/EP2010/004939 WO2011018224A1 (en)	2009-08-14	2010-08-12	Combination therapy of an afucosylated cd20 antibody with bendamustine
EP10747168.2A EP2464382B1 (en)	2009-08-14	2010-08-12	Combination therapy of an afucosylated cd20 antibody with bendamustine

Publications (1)

Publication Number	Publication Date
LTPA2017035I1 true LTPA2017035I1 (lt)	2017-11-27

Family

ID=41351729

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP10747168.2T LT2464382T (lt)	2009-08-14	2010-08-12	Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu
LTPA2017035C LTPA2017035I1 (lt)	2009-08-14	2017-10-31	Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP10747168.2T LT2464382T (lt)	2009-08-14	2010-08-12	Gydymas afukozintu anti-cd20 antikūnu kartu su bendamustinu

Country Status (34)

Country	Link
US (4)	US20110165151A1 (lt)
EP (1)	EP2464382B1 (lt)
JP (3)	JP5646626B2 (lt)
KR (1)	KR101425736B1 (lt)
CN (2)	CN102596245A (lt)
AR (1)	AR077866A1 (lt)
AU (1)	AU2010281866B2 (lt)
CA (1)	CA2769674C (lt)
CL (1)	CL2012000391A1 (lt)
CR (1)	CR20120036A (lt)
CY (2)	CY1119251T1 (lt)
DK (1)	DK2464382T3 (lt)
ES (1)	ES2630158T3 (lt)
HK (1)	HK1245145A1 (lt)
HR (1)	HRP20170972T1 (lt)
HU (2)	HUE033531T2 (lt)
IL (1)	IL217753A (lt)
LT (2)	LT2464382T (lt)
LU (1)	LUC00045I2 (lt)
MA (1)	MA33469B1 (lt)
MX (2)	MX355849B (lt)
MY (1)	MY163003A (lt)
NO (1)	NO2017054I1 (lt)
NZ (1)	NZ597666A (lt)
PL (1)	PL2464382T3 (lt)
PT (1)	PT2464382T (lt)
RS (1)	RS56146B1 (lt)
SG (1)	SG178324A1 (lt)
SI (1)	SI2464382T1 (lt)
SM (1)	SMT201700329T1 (lt)
TW (1)	TWI409079B (lt)
UA (1)	UA110096C2 (lt)
WO (1)	WO2011018224A1 (lt)
ZA (1)	ZA201200830B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE042914T2 (hu)	2003-11-05	2019-07-29	Roche Glycart Ag	CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
NZ583318A (en)	2007-07-16	2012-07-27	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN111499748A (zh)	2007-07-16	2020-08-07	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
ES2587392T3 (es)	2008-01-31	2016-10-24	Genentech, Inc.	Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
TWI500617B (zh)	2010-05-31	2015-09-21	Ono Pharmaceutical Co	Purine ketone derivatives
FR2976811A1 (fr) *	2011-06-22	2012-12-28	Lfb Biotechnologies	Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
KR20200058583A (ko) *	2011-08-16	2020-05-27	모르포시스 아게	항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HUE058855T2 (hu) *	2011-08-16	2022-09-28	Morphosys Ag	Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
FR2980110A1 (fr) *	2011-09-20	2013-03-22	Lfb Biotechnologies	Combinaison d'anticorps anti-cd20 et de bendamustine
BR112014012727B1 (pt)	2011-11-29	2022-10-25	Ono Pharmaceutical Co., Ltd	Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN103375132A (zh) *	2012-04-24	2013-10-30	长江大学	井下旋转冲击式钻井工具
ES2667420T3 (es)	2013-02-05	2018-05-10	Engmab Sàrl	Anticuerpos biespecíficos contra cd3epsilon y bcma
EP2762496A1 (en)	2013-02-05	2014-08-06	EngMab AG	Method for the selection of antibodies against BCMA
DK3003402T3 (en) *	2013-06-07	2018-04-16	Nordic Nanovector Asa	Combination therapy including rituximab and the radiolabelled HH1 monoclonal antibody
EP3122360B1 (en)	2014-03-25	2020-06-17	ONO Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
RS60349B8 (sr)	2014-09-23	2022-10-31	Hoffmann La Roche	Postupak upotrebe anti-cd79b imunokonjugata
ES2955554T3 (es)	2015-04-09	2023-12-04	Ono Pharmaceutical Co	Proceso para producir un derivado de purinona
RS60030B1 (sr)	2015-08-03	2020-04-30	Engmab Sarl	Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
EP3257866A1 (en) *	2016-06-17	2017-12-20	Academisch Medisch Centrum	Modified anti-tnf antibody and use thereof in the treatment of ibd
EP4295918A3 (en)	2016-11-02	2024-03-20	Bristol-Myers Squibb Company	Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CN110402097A (zh)	2016-12-07	2019-11-01	普罗根尼蒂公司	胃肠道检测方法、装置和系统
EP4108183A1 (en)	2017-03-30	2022-12-28	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
HUE061792T2 (hu)	2018-05-23	2023-08-28	Celgene Corp	Antiproliferatív vegyületek és BCMA és CD3 elleni bispecifikus antitest kombinált alkalmazásra
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3883636A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7287048B2 (ja)	2019-03-27	2023-06-06	セイコーエプソン株式会社	ロボット
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
DK2180007T4 (da)	1998-04-20	2017-11-27	Roche Glycart Ag	Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
EP1080113A4 (en)	1998-05-15	2002-04-17	Imclone Systems Inc	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
DK1176195T3 (da)	1999-04-09	2013-06-24	Kyowa Hakko Kirin Co Ltd	Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en)	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
ES2524694T3 (es)	2002-10-17	2014-12-11	Genmab A/S	Anticuerpos monoclonales humanos contra CD20
RS20100366A (sr)	2002-12-16	2011-04-30	Genentech, Inc.	Varijante imunoglobulina i njihova upotreba
NZ591970A (en)	2003-01-22	2012-11-30	Roche Glycart Ag	Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
AU2004241093B2 (en) *	2003-05-16	2009-08-27	Idera Pharmaceuticals, Inc.	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
CA2534077A1 (en)	2003-07-29	2005-02-10	Morphotek Inc.	Antibodies and methods for generating genetically altered antibodies with enhanced effector function
EP2502935B1 (en)	2003-08-22	2017-03-29	Biogen MA Inc.	Improved antibodies having altered effector function and methods for making the same
EP1663306A2 (en)	2003-09-05	2006-06-07	Genentech, Inc.	Antibodies with altered effector functions
HUE042914T2 (hu) *	2003-11-05	2019-07-29	Roche Glycart Ag	CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
JP5255435B2 (ja)	2005-04-26	2013-08-07	メディミューン，エルエルシー	ヒンジドメイン操作による抗体エフェクター機能の調節
US20090215639A1 (en)	2005-04-26	2009-08-27	Bioren, Inc.	Method of Producing Human IgG Antibodies with Enhanced Effector Functions
TWI478940B (zh)	2005-08-26	2015-04-01	Roche Glycart Ag	具有經改變細胞傳訊活性之改質抗原結合分子
ES2417147T3 (es) *	2005-10-21	2013-08-06	Revo Biologics, Inc.	Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2234641B1 (en) *	2008-01-03	2015-08-19	Genmab A/S	Monoclonal antibodies against cd32b
SG172792A1 (en) *	2009-01-16	2011-08-29	Glaxosmithkline Llc	Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody
JP5518179B2 (ja) *	2009-04-15	2014-06-11	インヴィスタテクノロジーズエスアエルエル	他の方法では非混和性の化合物の混和性の向上

2010
- 2010-08-11 TW TW099126813A patent/TWI409079B/zh active
- 2010-08-12 HR HRP20170972TT patent/HRP20170972T1/hr unknown
- 2010-08-12 NZ NZ597666A patent/NZ597666A/xx unknown
- 2010-08-12 SI SI201031491T patent/SI2464382T1/sl unknown
- 2010-08-12 SG SG2012008843A patent/SG178324A1/en unknown
- 2010-08-12 RS RS20170647A patent/RS56146B1/sr unknown
- 2010-08-12 AU AU2010281866A patent/AU2010281866B2/en active Active
- 2010-08-12 CA CA2769674A patent/CA2769674C/en active Active
- 2010-08-12 SM SM20170329T patent/SMT201700329T1/it unknown
- 2010-08-12 AR ARP100102968A patent/AR077866A1/es unknown
- 2010-08-12 KR KR1020127006528A patent/KR101425736B1/ko active Active
- 2010-08-12 JP JP2012524146A patent/JP5646626B2/ja active Active
- 2010-08-12 HU HUE10747168A patent/HUE033531T2/hu unknown
- 2010-08-12 PT PT107471682T patent/PT2464382T/pt unknown
- 2010-08-12 MX MX2014015198A patent/MX355849B/es unknown
- 2010-08-12 MY MYPI2012000606A patent/MY163003A/en unknown
- 2010-08-12 CN CN201080035971XA patent/CN102596245A/zh active Pending
- 2010-08-12 WO PCT/EP2010/004939 patent/WO2011018224A1/en not_active Ceased
- 2010-08-12 DK DK10747168.2T patent/DK2464382T3/en active
- 2010-08-12 EP EP10747168.2A patent/EP2464382B1/en active Active
- 2010-08-12 CN CN201710422477.2A patent/CN107261138A/zh active Pending
- 2010-08-12 PL PL10747168T patent/PL2464382T3/pl unknown
- 2010-08-12 ES ES10747168.2T patent/ES2630158T3/es active Active
- 2010-08-12 MX MX2012001782A patent/MX2012001782A/es active IP Right Grant
- 2010-08-12 LT LTEP10747168.2T patent/LT2464382T/lt unknown
- 2010-08-12 MA MA34585A patent/MA33469B1/fr unknown
- 2010-08-13 US US12/855,827 patent/US20110165151A1/en not_active Abandoned
- 2010-12-08 UA UAA201202678A patent/UA110096C2/ru unknown
2012
- 2012-01-19 CR CR20120036A patent/CR20120036A/es unknown
- 2012-01-26 IL IL217753A patent/IL217753A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00830A patent/ZA201200830B/en unknown
- 2012-02-08 US US13/368,465 patent/US20120315268A1/en not_active Abandoned
- 2012-02-14 CL CL2012000391A patent/CL2012000391A1/es unknown
2013
- 2013-01-18 HK HK18104879.8A patent/HK1245145A1/zh unknown
- 2013-03-06 US US13/787,532 patent/US20140044705A1/en not_active Abandoned
2014
- 2014-05-08 US US14/273,148 patent/US20160166688A9/en not_active Abandoned
- 2014-11-04 JP JP2014224221A patent/JP5963013B2/ja active Active
2016
- 2016-06-15 JP JP2016118739A patent/JP2016222673A/ja active Pending
2017
- 2017-07-03 CY CY20171100706T patent/CY1119251T1/el unknown
- 2017-10-26 CY CY2017034C patent/CY2017034I1/el unknown
- 2017-10-26 LU LU00045C patent/LUC00045I2/fr unknown
- 2017-10-26 NO NO2017054C patent/NO2017054I1/no unknown
- 2017-10-27 HU HUS1700041C patent/HUS000498I2/hu unknown
- 2017-10-31 LT LTPA2017035C patent/LTPA2017035I1/lt unknown

Also Published As

Publication number	Publication date
US20160166688A9 (en)	2016-06-16
NZ597666A (en)	2013-10-25
LUC00045I1 (lt)	2017-11-03
TW201110980A (en)	2011-04-01
HRP20170972T1 (hr)	2017-09-22
WO2011018224A1 (en)	2011-02-17
UA110096C2 (uk)	2015-11-25
SG178324A1 (en)	2012-03-29
AR077866A1 (es)	2011-09-28
MA33469B1 (fr)	2012-07-03
LT2464382T (lt)	2017-07-25
HK1245145A1 (zh)	2018-08-24
RS56146B1 (sr)	2017-11-30
EP2464382B1 (en)	2017-05-03
CN102596245A (zh)	2012-07-18
JP2015071611A (ja)	2015-04-16
JP5963013B2 (ja)	2016-08-03
LUC00045I2 (lt)	2018-02-26
RU2012109445A (ru)	2013-09-27
CR20120036A (es)	2012-04-18
US20120315268A1 (en)	2012-12-13
EP2464382A1 (en)	2012-06-20
IL217753A0 (en)	2012-03-29
KR101425736B1 (ko)	2014-08-01
PL2464382T3 (pl)	2017-09-29
CY1119251T1 (el)	2018-02-14
CA2769674C (en)	2018-01-23
ES2630158T3 (es)	2017-08-18
BR112012002855A2 (pt)	2016-11-01
US20140044705A1 (en)	2014-02-13
MX2012001782A (es)	2012-04-19
PT2464382T (pt)	2017-06-30
US20110165151A1 (en)	2011-07-07
JP5646626B2 (ja)	2014-12-24
JP2016222673A (ja)	2016-12-28
KR20120054068A (ko)	2012-05-29
ZA201200830B (en)	2012-10-31
CN107261138A (zh)	2017-10-20
SI2464382T1 (sl)	2017-08-31
CY2017034I2 (el)	2018-02-14
JP2013501740A (ja)	2013-01-17
NO2017054I1 (no)	2017-10-26
CY2017034I1 (el)	2018-02-14
CL2012000391A1 (es)	2012-08-24
AU2010281866B2 (en)	2016-05-12
IL217753A (en)	2016-10-31
HUE033531T2 (hu)	2021-12-28
CA2769674A1 (en)	2011-02-17
HUS1700041I1 (hu)	2017-11-28
AU2010281866A1 (en)	2012-02-02
MY163003A (en)	2017-07-31
US20150093376A1 (en)	2015-04-02
TWI409079B (zh)	2013-09-21
HUS000498I2 (hu)	2021-03-29
MX355849B (es)	2018-05-02
SMT201700329T1 (it)	2017-09-07
DK2464382T3 (en)	2017-07-17

Publication	Publication Date	Title
LTPA2017035I1 (lt)	2017-11-27	Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu
NO2024044I1 (no)	2024-10-08	Insulin icodec
BRPI0907231A2 (pt)	2019-09-24	pirrolpirimidinas e pirrolpiridinas
HRP20160737T1 (hr)	2016-07-15	Anti-her3-protutijela i njihove uporabe
PL2544682T3 (pl)	2016-08-31	Fitokannabinoidy w leczeniu glejaka
EP2414948A4 (en)	2012-12-05	APPLICATION SHARING
BR112013008905A2 (pt)	2017-07-11	mecanismo de dosagem e método de dosagem
DE112010001215A5 (de)	2012-07-05	Gurtaufrollersystem mit einsteuerglied
BR112014007243A2 (pt)	2017-04-11	composição, componentes e dispositivo de iluminação
HRP20160577T1 (hr)	2016-07-29	Liječenje osteoartritisa
FI20095020L (fi)	2010-07-13	Menetelmä aukirullaimen yhteydessä
ES1071902Y (es)	2010-07-22	Mecanismo de termosoldadura y precorte
FI20095999A0 (fi)	2009-09-30	Menetelmä pumppukäytön yhteydessä
DK2310037T3 (da)	2014-10-27	Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DK2306097T3 (da)	2019-10-21	Ventilenhed med flere funktioner
ES1070576Y (es)	2010-01-04	Bionda perfeccionada
PL389509A1 (pl)	2011-05-23	Bioanoda
FI8371U1 (fi)	2009-08-04	Järjestely taajuudenmuuttajassa
TH105708B (th)	2011-01-26	ขวดพร้อมปั๊ม
UY3886Q (es)	2010-03-26	Configuración aplicada en dispensador
UY3960Q (es)	2011-07-29	Configuración aplicada en licuadora
FI20096360A0 (fi)	2009-12-18	Bioliima ja puulevy
TH100148B (th)	2010-02-25	ที่วางแขน
UY4071Q (es)	2011-12-30	Configuración aplicada en triciclo
ES1069043Y (es)	2009-04-16	Recipiente perfeccionado